SHIFT AI Newsroom · GLOBAL
Trial Update: Ribupatide for Obesity Without Diabetes
A clinical trial is comparing the efficacy and safety of Ribupatide with Semaglutide and placebo in participants with obesity who do not have diabetes.
A clinical trial has been registered to evaluate the efficacy and safety of Ribupatide administered once weekly compared with Semaglutide and placebo in participants living with obesity who do not have diabetes. The trial is currently in the clinical trial stage, and no conclusions can be drawn about its safety or efficacy at this time.
What this means in the UK
This trial may provide insight into potential new treatments for obesity in the UK, but it's still in the clinical trial stage and not yet approved for use.
Known facts
- A clinical trial is comparing Ribupatide with Semaglutide and placebo in participants with obesity who do not have diabetes.